The search for a medicine for Down’s syndrome

Venue: Wellcome Trust Conference Centre Genome Campus

Location: Cambridge, United Kingdom

Event Date/Time: Sep 17, 2011 End Date/Time: Sep 17, 2011
Abstract Submission Date: Sep 01, 2011
Paper Submission Date: Sep 01, 2011
Report as Spam


There are at least 30,000 children and adults with Down’s syndrome in the UK who need this research – 700 new babies every year.
Our conference will be opened by Madam Jerome Lejeune, wife of the late Prof.Jerome Lejeune who dedicated his life to the discovery of a cure for Down’s syndrome. His work continues at the Foundation Jerome Lejeune in Paris with the support
of Madam Lejeune and a team of researchers. Their Research Director, Dr Henri Blehaut, will discuss the work of the Lejeune Foundation.
Chairing the day will be Dr. William C. Mobley, the Professor and Chair of the Department of Neurology and Neurological Sciences as well as the Director of the Center for Research and Treatment of Down Syndrome at Stanford University.
We welcome Dr David Smith and Dr Helga Refsum who lead the OPTIMA team at Oxford University where they have successfully trialled a treatment to slow the rate of brain atrophy seen in patients with mild
cognitive impairment. The potential for a similar medicine for slowing the early onset dementia seen in Down’s syndrome will be discussed.
From the USA we also have Dr Benjamine Tyko, Professor of Pathology and Cell Biology, researching the expression of the genes in people with Down’s syndrome. Epigenomics research is one of the keys to the discovery of a medicine that can correct the errors seen in the biochemistry caused by the extra genes in Trisomy 21.
Dr Andy Simmons from the Institute of Psychiatry will discuss neuroimaging as a vital research tool for testing the effects of a treatments on the brain and identifying differences in functioning. We will also be joined by many other respected researchers from Europe and the USA.
Clinicians can be sure they will receive an excellent view of the current research in Down’s syndrome. We are at a crucial moment in the field and possibilities for the future are hopeful. Join us and see why.